ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
Dow Jones
38.239,66
0,40%
Euro vs US Dollar
1,07005
0,00%
Bitcoin
63.133,06
-0,95%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) News

TEVA Teva Pharmaceutical Industries Ltd

13,89
0,64 (4,83%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Teva Pharmaceutical Industries Ltd TEVA NYSE Depository Receipt
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,64 4,83% 13,89 01:48:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
13,31 13,31 13,98 13,81 13,25
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
16.4.202423:43BWAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™..
16.4.202423:30GLOBEAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™..
16.4.202414:00BWTeva’s New Real-World Evidence Presented at the 2024 AAN..
11.4.202414:30BWTeva Confirms Efficacy and Safety of AJOVY® (fremanezumab)..
09.4.202422:30BWTeva to Host Conference Call to Discuss First Quarter 2024..
06.4.202419:00BWNew Pharmacokinetic Modeling Data Presented by Teva..
04.4.202414:30BWTeva and mAbxience Announce Strategic Global Licensing..
01.4.202414:30BWClinical Collaboration Agreement between Teva and Launch..
07.3.202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:43EDGAR2Form 3 - Initial statement of beneficial ownership of..
05.3.202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202412:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202412:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202412:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202412:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202412:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202412:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202412:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.2.202413:00BWTeva and Jiangsu Nhwa Forge Strategic Partnership to Promote..
24.2.202402:15GLOBEAlvotech and Teva Announce U.S. Approval of SIMLANDI®..
24.2.202402:15BWAlvotech and Teva Announce U.S. Approval of SIMLANDI®..
20.2.202414:30BWTeva Presents New Data Supporting Safety, Tolerability and..
13.2.202415:05IHMARKETNEWSHotter-Than-Expected Inflation Data Likely To Weigh On Wall..
12.2.202423:03IHMARKETNEWSDow Reaches New Record Closing High But Nasdaq, S&P 500 Give..
12.2.202415:13IHMARKETNEWSTeva Pharmaceutical, Urban Outfitters Upgraded
01.2.202413:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.2.202413:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.2.202413:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.2.202413:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202413:00EDGAR2Form 8-K - Current report
31.1.202413:00BWTeva Reports Growth in Fourth Quarter and Full Year 2023
31.1.202412:00BWTeva Announces Intention to Divest API Business as Part of..
02.1.202422:30BWTeva to Host Conference Call to Discuss Fourth Quarter and..
02.1.202414:50DJNCorcept Therapeutics Shares Slide Premarket on Loss in Teva..
28.12.202322:30BWTeva to Present at the 42nd Annual J.P. Morgan Healthcare..
14.12.202314:30BWTeva and Biolojic Design Announce Exclusive License..

Kürzlich von Ihnen besucht

NYSE
TEVA
Teva Pharmaceutical Indu...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten